Anti-Amyloid Beta Antibody Patient Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating Alzheimer's disease, particularly those targeting amyloid beta (Aβ) deposits, face challenges in identifying responsive patients and achieving therapeutic endpoints due to patient heterogeneity and replication issues in clinical trials, with existing anti-amyloid therapies showing limited success.
Innovation Solution
The approach involves stratifying patients based on tau burden in the brain and the presence of APOE e4 alleles to select those who will respond best to anti-Aβ antibody treatments, using specific dosing regimens of anti-N3pGlu Aβ antibodies to administer effective doses of 100 mg to 1400 mg every four weeks, tailored to individual patient profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-Aβ antibody treatments are administered to all Alzheimer's disease patients, then some patients may benefit from reduced Aβ deposits, but patient heterogeneity leads to inconsistent treatment responses and failure to achieve therapeutic endpoints
Solution Approach 1:
The patent segments the Alzheimer's disease patient population into distinct subgroups based on tau burden levels (high vs. low) and APOE e4 allele status. This segmentation allows identification of specific patient subsets (e.g., low tau burden + APOE e4 carriers) who are most likely to respond to anti-Aβ antibody therapy, thereby improving treatment response consistency while accounting for patient diversity
Solution Approach 2:
The patent applies local quality by tailoring treatment recommendations to specific patient characteristics rather than applying a uniform approach. Patients are evaluated individually based on their tau burden and APOE genotype, with treatment decisions optimized for each patient's specific profile, thereby resolving the contradiction between treating diverse populations and achieving consistent outcomes
2Adaptability or versatility
If clinical trials include diverse patient populations to reflect real-world Alzheimer's disease, then generalizability improves, but replication becomes difficult due to heterogeneity
Solution Approach 1:
The patent resolves this contradiction by segmenting the trial population into homogeneous subgroups based on biomarker profiles (tau burden and APOE status). Trials can be conducted within these predefined subgroups, ensuring each trial population is representative of a specific patient type while maintaining replicability across trials, as the same segmentation criteria can be applied consistently in future studies
3Duration of action of moving object
If anti-Aβ therapy is administered early in disease progression, then potential to slow progression is maximized, but identifying responsive patients becomes more challenging when tau burden is not yet elevated
Solution Approach 1:
The patent applies preliminary action by using APOE e4 allele status as a predictive biomarker to identify patients who are likely to respond to anti-Aβ therapy before initiating treatment. This allows early identification of responsive patients based on genetic predisposition, even before tau burden becomes elevated, thereby enabling early intervention in the right patient population
Solution Approach 2:
The patent implements feedback mechanisms by monitoring tau burden changes and Aβ deposition levels during treatment to assess patient responsiveness. This feedback allows adjustment of treatment strategies and identification of non-responders, resolving the difficulty of detecting patient responsiveness in early-stage disease
Data Source
AI summary
The invention is directed to treatment or prevention of a disease characterized by deposition of Aβ in the brain using anti-Aβ antibodies. The diseases that can be treated or prevented include, e.g., Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy. The invention is also related to, in some aspects, to selecting a human subject based on the tau burden in the human subjects' brain, who is responsive to treatment or prevention of a disease characterized by deposition of Aβ in the brain that includes administering anti-Aβ antibodies. The invention is also related to human subjects who have one or two alleles of APOE e4.